
Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Safety Signals of Bimekizumab Emerge in New FAERS Analysis
2
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
3
Legal Issues in Value-Based Care Contracts for Self-Insured Employers
4
ICYMI: Highlights From AACR 2025
5









































